(Q40443039)

20 September 2017

1 reference

title

Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction (English)

1 reference

20 September 2017

1 reference

P. Marcellin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7608489

14 June 2024

M. Pouteau

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7608489

14 June 2024

J. P. Benhamou

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A7608489

14 June 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=7608489

14 June 2024

publication date

1 March 1995

1 reference

full work available at URL

20 September 2017

https://api.elsevier.com/content/article/PII:0168827895802916?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

https://api.elsevier.com/content/article/PII:0168827895802916?httpAccept=text/plain

14 June 2024

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

14 June 2024

published in

Journal of Hepatology

1 reference

20 September 2017

volume

22

1 reference

20 September 2017

issue

3

1 reference

20 September 2017

page(s)

364-369

1 reference

A role for hepatitis C virus infection in type II cryoglobulinemia

20 September 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Cryoglobulinemia with vasculitis associated with hepatitis C virus infection

14 June 2024

2

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase

14 June 2024

3

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Liver/kidney microsome antibody type 1 and hepatitis C virus infection

14 June 2024

4

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease

14 June 2024

5

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Hepatitis C virus and Hashimoto's thyroiditis

14 June 2024

6

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

High prevalence of antibodies to hepatitis C virus (HCV) in patients with anti-thyroid autoantibodies

14 June 2024

8

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Anti-GOR and Anti-thyroid Autoantibodies in Patients with Chronic Hepatitis C

14 June 2024

9

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

14 June 2024

10

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Hepatitis C virus infection in anti-HIV positive and negative French homosexual men with chronic hepatitis: comparison of second- and third-generation anti-HCV testing

14 June 2024

11

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Latent autoimmune thyroid disease in patients with chronic HCV hepatitis

14 June 2024

12

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Reversibility of thyroid dysfunction induced by recombinant alpha interferon in chronic hepatitis C

14 June 2024

15

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Antithyroid peroxidase autoantibodies in thyroid diseases

14 June 2024

17

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Thyroid antibodies in blood donors: prevalence and clinical significance

14 June 2024

18

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Increased spreading of macrophages from mice treated with interferon inducers

14 June 2024

20

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity

14 June 2024

21

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

The interferons. Mechanisms of action and clinical applications

14 June 2024

23

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Recombinant alfa-2b-interferon therapy in untreated, stages A and B chronic lymphocytic leukemia. A preliminary report

14 June 2024

24

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Auto-immune thrombocytopenia related to interferon therapy

14 June 2024

25

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour

14 June 2024

26

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Development of type 1 diabetes mellitus during interferon alfa therapy for chronic HCV hepatitis

14 June 2024

27

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Autoimmune chronic hepatitis exacerbated by alpha-interferon

14 June 2024

28

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial

14 June 2024

31

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Induction of hyperthyroidism by interferon-alpha-2b

14 June 2024

32

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Thyroid dysfunction and liver injury following alpha-interferon treatment of chronic viral hepatitis

14 June 2024

33

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Sustained hypothyroidism induced by recombinant alpha interferon in patients with chronic hepatitis C.

14 June 2024

34

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Development of thyroid disease during therapy of chronic viral hepatitis with interferon alfa

14 June 2024

35

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

PRIMARY HYPOTHYROIDISM ASSOCIATED WITH INTERFERON THERAPY OF BREAST CANCER

14 June 2024

37

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon

14 June 2024

38

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Autoimmunity after alpha-interferon therapy for malignant carcinoid tumors

14 June 2024

39

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis

14 June 2024

40

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer

14 June 2024

41

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Does interferon-beta therapy induce thyroid autoimmune phenomena?

14 June 2024

42

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon

14 June 2024

43

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells

14 June 2024

44

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Hypothyroidism and goitre during interleukin-2 therapy without LAK cells

14 June 2024

45

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a

14 June 2024

46

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Reversible thyroid dysfunction during treatment with GM-CSF

14 June 2024

47

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

14 June 2024

48

1 reference

https://api.crossref.org/works/10.1016/0168-8278(95)80291-6

14 June 2024

Identifiers

1 reference

20 September 2017

1 reference